HISTORY

Beginning as a small local pharmacy in Jerusalem in the early 1980s, Rekah soon grew into a pharmaceutical trade store in the Jerusalem area. The pharmaceutical trade store continued to grow during the 1980s, adding suppliers and extending its distribution nationwide.

During the 1990s, the company expanded its activities to include production, acquiring its first production plant in Holon, Israel (Rekah). In 1994, the company went public on the Tel Aviv Stock Exchange (REKA).

The company continued to expand its production capabilities and acquired a big production site in Binyamina, Israel (Vitamed) in 2003. In 2008, the company entered the field of natural products and vitamins as part of the Derech Haim brand.

From 2012 to 2018, production infrastructures were expanded, an R&D unit was established and the company promoted registration and export of its products abroad. In 2015, FIMI, the leading private equity fund in Israel, became a partner in the company.

In 2019, the investment plan was accelerated in order to support the TEVA deal and the company's production of the relevant TEVA products, as well as preparations for exporting core products to Europe. In addition, the company built a modern logistics center in central Israel.

In 2021, Rekah acquired “Tree of Life”, a company that develops, manufactures, imports, markets and sells innovative medical devices and health products. This is the first strategic and synergistic acquisition of the Rekah Group, which allows it to enter the growing medical device field in Israel and around the world. This acquisition opens the door to a significant growth channel in Israel and abroad by immediately expanding the product portfolio with innovative products in new areas, marketing registration and distribution infrastructure in foreign markets, regulatory capabilities, and development in the field of medical devices. 
 
In 2023 Rakah purchased the Moraz company. Moraz specializes in the development and production of dermo-cosmetic products based on medicinal plants. The purchase of Moraz is strategic and synergistic and represents a significant avenue of growth in Israel and abroad by expanding the product portfolio in plant-based products, marketing and distribution infrastructure in foreign markets, development and registration capabilities in the field of herbal-based dermo-cosmetic products.

The two strategic and synergistic acquisitions of Tree of Life and Moraz strengthen the position of Rakah Group as a central and leading pharmaceutical company in Israel.

Milestones in REKAH’s History

1947
Establishment of a pharmaceutical manufacturing plant.
1984
Establishment of “Ophir” pharmaceutical marketing & distribution.
1991
Acquisition of “Shalpharm Marketing” (as infrastructure for a national distribution mechanism).
1993
Acquisition of the first production plant (Vitamad Holon), which manufactures unique pills and sterile ointments.
1994
Listed for trading on the Tel Aviv Stock Exchange.
1997
Establishment of a national distribution mechanism.
2003
Acquisition of the second manufacturing plant (Vitamad Binyamina), which manufactures antibiotic drugs, eye drops, dermatological ointments, antiseptic preparations, syrups and drops.
2005
First exports to African countries.
2008
Expansion of production and marketing activities in the field of vitamins and nutritional supplements, including the private label brand for Clalit Health Services.
2010
Establishment of a central logistic center.
2012
Establishment of the Vitamad production division and an operational consolidation.
2014
Expansion of production capacity - construction of penicillin and cephalosporin plants, upgrading and expansion of the sterile ophthalmic department. Establishment of a central R & D department.
2015
Entry of FIMI Fund (leading private equity firm in Israel) as a partner.
2016
Implementing a 3-year investment plan in the production division (automation, industrial infrastructure, laboratories, IT). Cooperation agreement for the development, manufacture and export of a core product for European markets.
2017
Expansion of R&D activities. Submission for registration in Europe.
2018
Strategic cooperation agreement with ‘Teva’ for the manufacture of Rx, OTC and hospital antiseptic products, for 10 years.
2019
Establishment of a dedicated production plant for steroid tablets. Establishment of a dedicated plant for antiseptic preparations. An innovative agreement for the supply of prescription drugs to the home of Leumit HMO members. Construction of a modern logistics center in central Israel.
2021
Start marketing a steroid product
in the UK
Purchase TOL
Bella Online sale
2022
Inauguration of the R&D and Registration Center in Kfar Saba
2023
Moraz acquisition
and the story continues...